Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ethylestrenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 2/20 | 0.76 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | ESR1 | P03372 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 0.76 |
| ▸ | PGR | P06401 | 4/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.70 |
| ▸ | MAOA | P21397 | 1/20 | 0.70 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylestrenol SCHEMBL11217999 | 1.00 | SLC6A4 (1.00) | SLC6A4ESR1CYP2C19CHRM2SLC6A2 | |
| Ethylestrenol SCHEMBL28817294 | 0.94 | SLC6A4 (0.89) | SLC6A4ESR1CYP2C19CHRM2SLC6A2 | |
| Ethylestrenol SCHEMBL5491436 | 0.94 | SLC6A4 (0.88) | SLC6A4ESR1CYP2C19CHRM2SLC6A2 | |
| Allylestrenol SCHEMBL19645390 | 0.86 | ESR1 (1.00) | SLC6A4ESR1CYP2C19CHRM2SLC6A2 | |
| Allylestrenol SCHEMBL29648200 | 0.86 | ESR1 (1.00) | SLC6A4ESR1CYP2C19CHRM2SLC6A2 | |
| Allylestrenol SCHEMBL329623 | 0.86 | ESR1 (1.00) | SLC6A4ESR1CYP2C19CHRM2SLC6A2 | |
| Allylestrenol SCHEMBL10406336 | 0.86 | ESR1 (1.00) | SLC6A4ESR1CYP2C19CHRM2SLC6A2 | |
| SCHEMBL11856861 | 0.86 | SLC6A4 (0.75) | SLC6A4ESR1CYP2C19CHRM2SLC6A2 | |
| SCHEMBL21807745 | 0.85 | CYP2C19 (0.74) | SLC6A4ESR1CYP2C19CHRM2SLC6A2 | |
| Ethylestrenol SCHEMBL28086107 | 0.84 | SLC6A4 (0.71) | SLC6A4ESR1CYP2C19CHRM2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1995 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612223-B1 | TREATING MALE SENESCENCE | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-07-31 | — | — | EP | claimed |
| US-20240050440-A1 | THERAPEUTIC TARGETS AND AGENTS FOR THE TREATMENT OF TRIOSEPHOSPHATE ISOMERASE (TPI) DEFICIENCY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-02-15 | — | — | US | claimed |
| CN-115624658-A | Degradable uterine cavity administration device and preparation method thereof | 苏州纳晶医药技术有限公司 | 2023-01-20 | — | — | CN | claimed |
| WO-2022147217-A1 | THERAPEUTIC TARGETS AND AGENTS FOR THE TREATMENT OF TRIOSEPHOSPHATE ISOMERASE (TPI) DEFICIENCY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-07-07 | — | — | WO | claimed |
| CN-109925538-B | Elastic membrane, preparation method and application thereof | 易浦润（上海）生物技术有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-109925537-B | Elastic membrane, preparation method and application thereof | 易浦润（上海）生物技术有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-109925539-B | Elastic membrane, preparation method and application thereof | 易浦润（上海）生物技术有限公司 | 2021-12-07 | — | — | CN | claimed |
| US-11090307-B2 | Treating male senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-17 | — | — | US | claimed |
| CN-112494464-A | Elastic film and preparation method thereof | 易浦润（上海）生物技术有限公司 | 2021-03-16 | — | — | CN | claimed |
| US-10940151-B2 | Methods for treating renal disease | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-03-09 | — | — | US | claimed |
| US-5340585-A | Administering slow release formulation of gonadotropin hormone releasing hormone and estrogen | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1994-08-23 | — | — | US | claimed |
| US-5340586-A | Methods and formulations for use in treating oophorectomized women | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1994-08-23 | — | — | US | claimed |
| EP-0538443-A4 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS | — | 1993-12-08 | — | — | EP | claimed |
| EP-0538443-A1 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS. | UNIV SOUTHERN CALIFORNIA (US) | 1993-04-28 | — | — | EP | claimed |
| WO-1992018107-A1 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1992-10-29 | — | — | WO | claimed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | claimed |
| EP-0479867-A1 | COMPOSITIONS USEFUL AS CONTRACEPTIVES IN MALES. | COHEN MICHAEL (NL) | 1992-04-15 | — | — | EP | claimed |
| WO-1991000095-A1 | COMPOSITIONS USEFUL AS CONTRACEPTIVES IN MALES | COHEN MICHAEL (NL) | 1991-01-10 | — | — | WO | claimed |
| CN-1048327-A | Contraceptive composition for male | COHEN MICHAEL (NL) | 1991-01-09 | — | — | CN | claimed |
| EP-0324037-A1 | Method of treatment of central nervous system diseases such as Alzheimer's disease and Parkinson's disease and method of diagnosing Alzheimer's disease | Aroonsakul, Chaovanee (US) | 1989-07-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11090307-B2 | Treating male senescence | RIPK3, RIPK1, MLKL | AR 646/4885SLC6A4 4802/4885ESR1 1201/4885 |
| US-10940151-B2 | Methods for treating renal disease | LDLR, APOL1, APOB | AR 3667/4885SLC6A4 3988/4885ESR1 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.